Cannabinoids Explained: Complete Guide to THC, CBD, CBG, CBN, CBC, THCV and More

Cannabinoids are naturally occurring compounds found in marijuana and hemp that can interact with the human body in remarkably different ways.

THC is responsible for most of marijuana’s intoxicating effects. CBD does not produce the same high and has become one of the most widely researched cannabis compounds. Lesser-known cannabinoids such as CBG, CBN, CBC, THCV and CBDV are increasingly appearing in marijuana and hemp products, but the science behind them varies enormously.

Some cannabinoids have been studied in thousands of people. Others have been tested mainly in cells or animals. A few have barely been studied at all.

That distinction matters.

Cannabis products are increasingly marketed with claims that CBN promotes sleep, THCV suppresses appetite, CBG reduces anxiety or THCP is dramatically stronger than THC. Some of those claims have a scientific basis worth investigating. Others go substantially further than existing human evidence supports.

This guide explains the major cannabinoids found in marijuana and hemp, how they are produced, whether they are intoxicating, how they interact with the endocannabinoid system and what researchers actually know about their potential effects.

Last updated: September 2026

Cannabinoids are a broad family of chemical compounds that can interact with cannabinoid receptors or other biological signaling systems.

The marijuana plant produces a large number of these compounds. Researchers have identified well over 100 phytocannabinoids, with recent scientific reviews describing more than 150 and, depending on how related compounds are classified, roughly 160 minor cannabinoids.

Only a small fraction have been studied extensively.

THC and CBD account for the overwhelming majority of cannabinoid research. CBG, CBN, CBC, THCV, CBDV and acidic cannabinoids such as THCA and CBDA have attracted growing scientific interest, but their evidence bases remain much smaller.

Cannabinoids are not all chemically or pharmacologically interchangeable. Two compounds can come from the same plant and have dramatically different effects.

The word cannabinoid can refer to more than compounds found in marijuana.

There are three broad categories.

Phytocannabinoids are cannabinoids produced by plants, most notably Cannabis sativa.

They include:

THC CBD CBG CBN CBC THCV CBDV THCA CBDA CBGA THCP

These are the cannabinoids most consumers encounter in marijuana and hemp products.

Endocannabinoids are cannabinoid-like signaling molecules produced naturally by the human body.

The two best studied are:

Anandamide, also called AEA

2-arachidonoylglycerol, commonly called 2-AG

The human body produces these compounds whether or not a person ever uses marijuana.

Endocannabinoids are part of the endocannabinoid system, a signaling network involved in regulating numerous physiological processes.

Scientists can also manufacture compounds that interact with cannabinoid receptors.

Some are legitimate medications or research compounds. Dronabinol, for example, is synthetic delta-9 THC used in FDA-approved prescription medications.

Others are recreational compounds manufactured through chemical conversion or synthesis.

Commercial delta-8 THC is a good example. Delta-8 occurs naturally in cannabis only in small quantities, so much of the concentrated delta-8 sold commercially is produced by chemically converting CBD.

Synthetic cannabinoid drugs sold illicitly under names such as Spice or K2 are another category entirely. They can activate cannabinoid receptors much more strongly and unpredictably than THC and should not be confused with marijuana.

There is no single universally agreed number because scientists continue identifying compounds and classification methods differ.

Older references commonly state that cannabis contains more than 100 cannabinoids.

More recent scientific literature describes more than 150 phytocannabinoids, with some reviews estimating that about 160 minor cannabinoids have now been identified.

Only a relatively small group occurs in concentrations high enough or has been studied enough to be familiar to consumers.

THC and CBD remain by far the best known.

One of the most important things to understand about cannabinoids is that the living marijuana plant does not primarily manufacture THC and CBD in the forms consumers recognize.

Instead, it produces acidic cannabinoids.

A key compound is cannabigerolic acid, or CBGA.

CBGA can be converted by plant enzymes into several major cannabinoid acids, including:

CBGA → THCA CBGA → CBDA CBGA → CBCA

Those compounds can then lose a carbon dioxide molecule through a process called decarboxylation:

THCA → THC CBDA → CBD CBCA → CBC CBGA → CBG

Heat accelerates this process.

That is why smoking, vaping or cooking marijuana changes its cannabinoid chemistry.

Not exactly.

CBG is frequently called the “mother cannabinoid” because marijuana marketing materials often describe it as the compound from which THC, CBD and other cannabinoids originate.

The more scientifically accurate statement is that CBGA, not CBG, is a major biosynthetic precursor.

The marijuana plant uses CBGA to produce THCA, CBDA and CBCA.

CBG is primarily formed when CBGA itself undergoes decarboxylation.

So while CBG belongs to the same cannabinoid family and is closely connected to that pathway, calling CBG itself the direct precursor of THC and CBD is an oversimplification.

Decarboxylation is a chemical reaction in which cannabinoid acids lose a carboxyl group and become their neutral forms.

The best-known example is:

THCA → THC

Fresh marijuana flower typically contains much more THCA than active delta-9 THC.

Heating the flower through smoking, vaping or cooking rapidly converts much of that THCA into THC.

Decarboxylation also occurs gradually during drying, aging and storage.

The same process converts CBDA into CBD, CBGA into CBG and CBCA into CBC.

The endocannabinoid system, often abbreviated ECS, is a biological signaling network present throughout the human body.

Its major components include:

Cannabinoid receptors

Endocannabinoids produced by the body

Enzymes responsible for producing and breaking down endocannabinoids

The two best-characterized endocannabinoids are anandamide and 2-AG.

They help regulate signaling between cells and are involved in processes that include appetite, pain, memory, stress responses, immune function and nervous-system activity.

Importantly, the endocannabinoid system did not evolve because humans consume marijuana.

Scientists discovered the system after studying how THC affects the body. The receptors already existed because the body produces its own signaling molecules that activate them.

CB1 and CB2 are the two best-established cannabinoid receptors.

CB1 receptors are particularly abundant in the brain and central nervous system, although they are also found elsewhere in the body.

Their distribution helps explain many of THC’s effects.

When THC activates CB1 receptors, it can alter:

Mood

Memory

Appetite

Coordination

Perception

Pain processing

Reward

Time perception

This CB1 activity is also the main reason THC can produce intoxication.

CB2 receptors are strongly associated with immune cells and peripheral tissues, although researchers have also identified CB2 activity within the nervous system.

They are involved in immune and inflammatory signaling.

The old description that CB1 exists only in the brain while CB2 exists only in the immune system is too simplistic. Both receptor systems have broader distributions.

This is another common misconception.

THC has substantial direct activity at CB1 and CB2 receptors.

CBD does not.

CBD has relatively low affinity for the classic cannabinoid receptors and appears to influence numerous molecular targets and signaling pathways.

Minor cannabinoids can interact with systems including:

Transient receptor potential, or TRP, channels

Serotonin receptors

Adrenergic receptors

Peroxisome proliferator-activated receptors, or PPARs

GPR55

Other enzymes, receptors and ion channels

This is why describing every cannabinoid simply as something that “binds to the endocannabinoid system” misses much of their pharmacology.

THC is the primary intoxicating cannabinoid in marijuana.

When people say “THC” without specifying a form, they usually mean delta-9-tetrahydrocannabinol.

THC acts mainly as a partial agonist of CB1 and CB2 cannabinoid receptors. Its activity at CB1 receptors in the brain produces marijuana’s characteristic high.

Possible acute effects can include:

Euphoria

Relaxation

Altered sensory perception

Increased appetite

Changes in time perception

Drowsiness

Reduced short-term memory

Slower reaction time

Impaired coordination

Anxiety or paranoia in some people

THC is one of the most thoroughly studied cannabinoids.

Synthetic delta-9 THC, called dronabinol, is used in FDA-approved medications for conditions including chemotherapy-related nausea and vomiting and anorexia associated with weight loss in people with AIDS.

Another synthetic cannabinoid medication, nabilone, has a structure similar to THC and is also FDA approved for chemotherapy-related nausea and vomiting.

The marijuana plant itself is not FDA approved as a treatment for any disease.

For a much deeper look at THC, see The Marijuana Herald’s complete guide to THC.

CBD is the second best-known cannabinoid and differs substantially from THC.

It is not intoxicating in the way THC is and does not normally produce marijuana’s characteristic high.

CBD also does not strongly activate CB1 receptors.

Instead, it has a complex pharmacological profile involving the endocannabinoid system and numerous other molecular targets.

CBD has attracted enormous attention for potential applications involving:

Epilepsy

Anxiety

Pain

Inflammation

Sleep

Neurological disorders

Psychiatric disorders

However, the strength of evidence differs enormously between conditions.

The strongest clinical evidence for CBD involves certain seizure disorders.

The FDA-approved medication Epidiolex contains purified cannabis-derived CBD and is approved to treat seizures associated with:

Lennox-Gastaut syndrome

Dravet syndrome

Tuberous sclerosis complex

That does not mean over-the-counter CBD oils have been proven to treat those conditions.

Prescription CBD is manufactured to pharmaceutical standards, administered at carefully controlled doses and monitored for potential adverse effects and drug interactions.

For many other popular CBD uses, research remains mixed, limited or incomplete.

No.

CBD is generally well tolerated in many studies, but “non-intoxicating” does not mean biologically inactive or risk-free.

Potential effects can include:

Drowsiness

Diarrhea

Changes in appetite

Drug interactions

Changes in liver enzymes

A 2025 FDA-led randomized trial involving healthy adults found that 5.6% of participants receiving CBD for four weeks developed liver enzyme elevations greater than three times the upper limit of normal, compared with none receiving placebo.

CBD can also affect the metabolism of other medications.

Anyone taking prescription drugs should be particularly cautious about assuming that an over-the-counter CBD product cannot interact with them.

CBG is one of the most prominent minor cannabinoids.

It is generally considered non-intoxicating and does not produce the classic THC high.

CBG interacts with multiple biological targets, including cannabinoid receptors, adrenergic receptors and several TRP channels.

Research has investigated CBG for possible effects involving:

Anxiety

Inflammation

Pain

Neurological conditions

Gastrointestinal disorders

Appetite

Antibacterial activity

Most of those areas remain dominated by laboratory and animal research.

Human evidence is only beginning to develop.

A notable 2024 double-blind, placebo-controlled crossover trial tested 20 milligrams of hemp-derived CBG in 34 healthy adults.

Researchers reported reductions in anxiety and stress compared with placebo and unexpectedly found better performance on a verbal memory test.

They found no evidence of intoxication or motor impairment.

The findings are intriguing, but one small study cannot establish CBG as an anxiety treatment or prove that the effects will occur in broader populations.

Larger independent trials are needed.

This is a useful example of how minor cannabinoid research should be interpreted: promising does not mean proven.

CBN is unusual because it is associated less with fresh marijuana production than with the breakdown of THC.

As THC is exposed to oxygen, light and time, some of it can oxidize into CBN.

That is why aged marijuana may contain higher CBN levels than fresh flower.

CBN has relatively weak activity at CB1 compared with THC and has historically been described as mildly psychoactive, although its intoxicating effects in humans are much less clear and substantially weaker than delta-9 THC.

CBN is now heavily marketed as a sleep cannabinoid.

But is that reputation supported by science?

There is now some human evidence, but it remains limited and mixed.

A randomized placebo-controlled study involving 293 participants with poor sleep tested 20 milligrams of CBN alone and in combination with different CBD doses for seven nights.

CBN did not significantly improve the study’s primary sleep-quality outcome compared with placebo, although it was associated with fewer nighttime awakenings and lower overall sleep disturbance.

A separate randomized crossover trial published in 2026 studied 20 adults with diagnosed insomnia who received either 30 milligrams of CBN, 300 milligrams or placebo.

CBN did not significantly improve the primary outcome of wake time after sleep onset. However, the 300-milligram dose improved some secondary outcomes, including subjective sleep quality and sleep-onset latency.

That is a much more complicated picture than the common marketing claim that CBN is simply “the sleep cannabinoid.”

There are legitimate signals worth studying, but CBN has not been established as a clinically proven sleep medication.

CBC is another naturally occurring cannabinoid produced when CBCA decarboxylates.

CBC is generally considered non-intoxicating.

Unlike THC, it appears to have little direct activity at CB1 receptors. Research suggests that CBC interacts more substantially with several TRP channels and other molecular targets.

Scientists have investigated CBC for possible:

Pain-modulating effects

Anti-inflammatory activity

Neuroprotective effects

Antimicrobial activity

Effects on mood-related pathways

Dermatological applications

Cancer-related mechanisms

The key word is possible.

A major 2026 scientific review of CBC noted that despite extensive preclinical research, clinical trials in humans are essentially absent.

That means claims about what CBC “does” for consumers should be treated cautiously.

CBC is scientifically interesting, but its potential medical applications remain largely experimental.

THCV has a structure similar to THC, but the two compounds do not behave identically.

THCV is part of a group of cannabinoids with shorter propyl side chains.

Its effects appear to vary by dose and biological context. Research has found complex activity at cannabinoid receptors, including CB1 antagonism under some conditions.

THCV is frequently marketed as:

“Energy THC”

“Skinny THC”

“Diet marijuana”

An appetite suppressant

Those descriptions go well beyond what has been established in humans.

Human evidence remains insufficient to conclude that THCV is an effective weight-loss cannabinoid or appetite suppressant.

One randomized clinical trial involving 62 people with type 2 diabetes tested THCV, CBD and combinations of the two for 13 weeks.

Participants receiving 5 milligrams of THCV twice daily experienced improvements in fasting plasma glucose and some measures of pancreatic beta-cell function compared with placebo.

However, THCV did not improve the study’s primary HDL cholesterol endpoint, and this trial was not proof that THCV causes weight loss.

THCV remains scientifically interesting for metabolic research, but the popular “diet cannabinoid” label is ahead of the evidence.

THCV should not simply be described as a weaker form of THC.

Its pharmacology is dose-dependent and substantially different.

Human research at studied doses has generally not demonstrated the classic intoxication associated with delta-9 THC, although high-dose and different THCV isomers remain incompletely characterized.

The safest description is that THCV does not reliably behave like THC in humans, and its effects depend on dose, formulation and molecular form.

CBDV is structurally related to CBD and, like CBD, is generally considered non-intoxicating.

Researchers have investigated CBDV particularly for neurological conditions.

One of the largest human studies was a Phase II randomized controlled trial involving 162 adults with inadequately controlled focal seizures.

Participants receiving CBDV experienced a substantial reduction in seizures from baseline, but the placebo group improved by a similar amount.

The difference between CBDV and placebo was not statistically significant.

This result is important because it demonstrates why promising animal research does not always translate into successful human treatment.

CBDV remains under investigation, but there is currently no established medical use comparable with prescription CBD.

THCA is the acidic precursor to THC.

Fresh marijuana flower generally contains far more THCA than active delta-9 THC.

THCA does not strongly activate CB1 receptors and does not produce the classic marijuana high in its unheated form.

When THCA is heated, however, it decarboxylates into THC.

That means:

Smoking converts THCA to THC.

Vaping converts THCA to THC.

Cooking marijuana converts THCA to THC.

Even storage and aging can gradually convert some THCA.

This is why describing a high-THCA marijuana flower product as “non-intoxicating” can be misleading if that product is intended to be smoked or vaped.

Laboratory and animal studies have investigated THCA for potential anti-inflammatory, neuroprotective, anti-nausea and other biological effects.

Human clinical evidence is much more limited.

THCA should therefore not be treated as a clinically established therapy simply because preclinical studies have identified interesting mechanisms.

CBDA is the acidic precursor to CBD.

It occurs naturally in raw cannabis and converts into CBD through decarboxylation.

CBDA is non-intoxicating.

Preclinical research has investigated CBDA for possible effects involving nausea, inflammation, seizures and serotonin-related pathways.

However, controlled human evidence remains sparse.

Like other acidic cannabinoids, CBDA also presents practical research challenges because it can be chemically unstable and convert into other compounds during processing and storage.

CBGA is one of the most important cannabinoids for understanding how the plant creates its chemical profile.

It is a central biosynthetic precursor used to produce:

THCA

CBDA

CBCA

This is why CBGA, rather than CBG itself, is the compound most accurately described as a major “parent” cannabinoid.

CBGA can also decarboxylate into CBG.

Although researchers are examining CBGA’s own biological effects, most discussion of CBGA remains centered on its crucial role in cannabinoid biosynthesis.

CBCA is the acidic precursor to CBC.

The marijuana plant produces CBCA from CBGA using an enzyme known as CBC acid synthase.

When CBCA loses carbon dioxide through decarboxylation, it becomes CBC.

Compared with THC, CBD and even CBG, relatively little human research has been conducted on CBCA itself.

THCP attracted enormous attention after researchers identified it in Cannabis sativa in 2019.

Its structure resembles THC but contains a longer seven-carbon side chain.

In laboratory testing, THCP showed about 33 times greater binding affinity for the CB1 receptor than delta-9 THC.

This quickly turned into online claims that:

“THCP is 33 times stronger than THC.”

That is not what the study proved.

There is no good human evidence establishing that THCP produces a high 33 times stronger than THC.

The 33-fold figure refers to receptor binding affinity in laboratory experiments.

Receptor affinity and real-world human potency are not the same thing.

A compound’s actual effects depend on:

How much reaches the bloodstream

How easily it enters the brain

How strongly it activates a receptor after binding

How rapidly it is metabolized

Its active metabolites

Dose

Route of administration

Individual biology

Animal research found that THCP produced THC-like cannabinoid effects, supporting the conclusion that it is biologically active.

But claims assigning THCP a precise human potency relative to THC remain unsupported.

Delta-8 THC is a close chemical relative of delta-9 THC.

It occurs naturally in cannabis but generally only at low concentrations.

Most concentrated delta-8 THC products are therefore not made by simply extracting large quantities of naturally occurring delta-8 from hemp.

Instead, manufacturers commonly convert hemp-derived CBD into delta-8 THC through chemical processing.

Delta-8 is intoxicating.

Research into its effects and safety is much less extensive than research into delta-9 THC.

The FDA has also raised concerns about potential contaminants and byproducts created during some chemical conversion processes used to manufacture concentrated delta-8 products.

The agency has received adverse-event reports involving delta-8 products and has warned that these products have not been evaluated or approved for safe use.

Consumers may encounter products containing compounds such as:

Delta-10 THC

HHC

THC-O

HHCP

THC-P variants

Other hydrogenated or modified cannabinoids

Some may occur naturally only in trace amounts. Others are primarily produced through chemical conversion or synthesis.

They should not automatically be treated as equivalent to naturally abundant marijuana cannabinoids.

Human safety data for many of these compounds are extremely limited.

A product being sold commercially is not evidence that its pharmacology, long-term effects or appropriate dosage have been established.

The clearest answer is delta-9 THC.

Delta-9 THC is the primary cannabinoid responsible for marijuana intoxication.

Delta-8 THC is also intoxicating.

Other THC-related cannabinoids and analogues may produce intoxication depending on their pharmacology and dose.

CBD, CBG and CBC are generally considered non-intoxicating.

THCA is not intoxicating like THC until it is converted through decarboxylation.

CBN appears substantially less intoxicating than THC, with its independent psychoactive effects still incompletely defined.

THCV has complex dose-dependent pharmacology and should not simply be categorized as ordinary THC.

THCP has strong CB1 receptor affinity and produces cannabinoid-like effects in animals, but reliable human dose-response data remain lacking.

A cannabinoid does not need to make someone high to have biological effects.

CBD is the clearest example.

CBD is non-intoxicating but can:

Interact with medications

Influence liver enzymes

Cause drowsiness

Affect multiple receptor systems

Produce measurable physiological effects

The same principle applies to minor cannabinoids.

“Doesn’t get you high” and “does nothing” are not the same statement.

Cannabinoids and terpenes are different families of compounds.

Cannabinoids include THC, CBD, CBG and other compounds discussed in this guide.

Terpenes are aromatic compounds responsible for much of marijuana’s smell and flavor.

Common cannabis terpenes include:

Myrcene

Limonene

Pinene

Linalool

Terpinolene

Beta-caryophyllene

Terpenes are also found throughout nature. Limonene occurs in citrus fruit, pinene in numerous coniferous plants and linalool in lavender.

One interesting exception illustrates why cannabis chemistry can be complicated: beta-caryophyllene is a terpene that can activate CB2 cannabinoid receptors.

That does not make beta-caryophyllene a phytocannabinoid.

Cannabinoids and terpenes should be treated as separate chemical categories even when they interact with some of the same biological systems.

The entourage effect is the idea that combinations of cannabinoids, terpenes and other cannabis compounds may produce effects that differ from isolated compounds.

The concept is scientifically plausible.

Different marijuana compounds can clearly interact with one another.

But the popular version of the entourage effect often goes further, claiming that full-spectrum marijuana products reliably produce superior or predictable effects because every cannabinoid and terpene works together synergistically.

That has not been firmly demonstrated.

Scientific reviews have concluded that evidence for a consistent, predictable entourage effect remains limited.

Some cannabinoid interactions are real without proving a universal entourage effect.

For example, a controlled human study found that a large oral dose of CBD taken with THC increased THC exposure and intensified several THC-related effects compared with the same dose of THC alone.

That demonstrates that one cannabinoid can alter another cannabinoid’s effects.

It does not prove that every full-spectrum product is inherently better than an isolate.

Not reliably.

A common claim is that CBD simply blocks or neutralizes THC.

The real relationship is much more complicated.

CBD can influence THC pharmacology, but the outcome depends on:

Dose

Ratio

Timing

Route of administration

Individual biology

With some formulations and doses, CBD may modify certain THC effects.

With high oral CBD doses, research has shown that CBD can slow THC metabolism and actually increase THC exposure and some of its effects.

Consumers should therefore not assume that taking CBD will automatically reverse excessive THC intoxication.

Cannabinoid products are often marketed using three terms.

Full-spectrum products generally contain multiple cannabinoids and other cannabis compounds.

Depending on the source and formulation, they may contain THC.

Broad-spectrum products generally contain multiple cannabinoids and other plant compounds while attempting to remove THC.

However, terminology and manufacturing practices are not perfectly standardized.

An isolate is intended to contain essentially one purified cannabinoid.

CBD isolate is the most common example.

These descriptions can be useful, but actual laboratory results are more informative than marketing terminology.

Cannabinoid ratios describe the relative amounts of two or more cannabinoids in a product.

For example, a CBD:THC ratio of 2:1 means the product contains twice as much CBD as THC.

Common examples include:

Always check which cannabinoid is listed first. A CBD:THC ratio of 2:1 means something different from a THC:CBD ratio of 2:1.

Ratios also do not tell you the total dose.

A serving containing 2 milligrams CBD and 1 milligram THC has the same 2:1 ratio as one containing 20 milligrams CBD and 10 milligrams THC. The second contains ten times as much of each cannabinoid.

Some products list three or more cannabinoids, such as THC:CBD:CBN. The same principle applies: each number represents the relative amount of the corresponding compound.

When comparing products, check both the ratio and the actual milligrams of each cannabinoid per serving. Also distinguish between amounts per serving and amounts in the entire package.

A certificate of analysis, commonly called a COA, can show which cannabinoids a laboratory detected and their concentrations.

Common entries include:

THCA

Delta-9 THC

CBD

CBDA

CBG

CBGA

CBN

CBC

THCV

Cannabinoids may be reported as:

Percentage by weight

Milligrams per gram

Milligrams per serving

Milligrams per package

Understanding acidic cannabinoids is particularly important.

A flower product can contain relatively little delta-9 THC while containing a large amount of THCA that converts to THC when heated.

That is why laboratories and regulators often calculate “total THC.”

A commonly used formula is:

Total THC = delta-9 THC + (THCA × 0.877)

The 0.877 factor accounts for the molecular weight lost when THCA releases carbon dioxide during decarboxylation.

A similar calculation may be used for CBD:

Total CBD = CBD + (CBDA × 0.877)

Two marijuana products with identical THC percentages can produce different experiences.

Factors include:

Dose actually consumed

Cannabinoid ratios

Terpenes

Route of administration

Tolerance

Metabolism

Food intake

Previous marijuana experience

Individual genetics and biology

Product formulation

THC percentage remains important, particularly when comparing flower or concentrates, but it does not perfectly predict how strong a product will feel to a particular person.

Route of administration changes cannabinoid pharmacology.

When THC is inhaled, it reaches the bloodstream and brain rapidly.

When THC is swallowed, it passes through the digestive system and liver.

The liver converts some THC into 11-hydroxy-THC, an active metabolite that contributes to the different intensity and duration often associated with edibles.

Oral CBD can also undergo extensive metabolism.

Food, particularly high-fat meals, can substantially affect cannabinoid absorption.

This helps explain why identical milligram doses can produce different effects depending on the formulation and how they are consumed.

THC and CBD.

They have overwhelmingly larger human evidence bases than minor cannabinoids such as CBG, CBN, CBC or THCV.

That does not mean every claim involving THC or CBD has been proven.

It means scientists know considerably more about their pharmacology, safety and effects.

Among minor cannabinoids:

CBG now has some controlled human evidence.

CBN has several modern sleep studies, but results remain mixed.

THCV has limited clinical research, including metabolic studies.

CBDV has reached controlled clinical trials but has not demonstrated efficacy in some major studies.

CBC remains largely preclinical.

THCA and CBDA remain dominated by laboratory and animal research.

THCP has extremely limited human evidence.

The gap between marketing and clinical evidence generally becomes larger as cannabinoids become rarer.

Yes, but the distinction between approved cannabinoid drugs and commercial marijuana products is important.

The FDA has approved Epidiolex, a purified cannabis-derived CBD medication used for specific seizure disorders.

The agency has also approved synthetic cannabis-related medications containing:

Dronabinol, synthetic delta-9 THC

Nabilone, a synthetic cannabinoid structurally similar to THC

The FDA has not approved the marijuana plant itself as a treatment for any disease or condition.

It has also not approved ordinary retail CBD, CBG, CBN or other cannabinoid supplements as treatments for diseases simply because similar compounds are being investigated medically.

Yes.

CBD is particularly well documented for drug interactions because it can affect liver enzymes involved in metabolizing medications.

THC and other cannabinoids may also interact with medications through pharmacological or metabolic mechanisms.

Potential concerns can involve:

Anti-seizure medications

Blood thinners

Sedatives

Some antidepressants and psychiatric medications

Blood-pressure medications

Drugs metabolized through certain cytochrome P450 enzymes

Research on drug interactions involving minor cannabinoids remains much less complete.

That uncertainty is itself important.

A lack of known interactions does not prove that an understudied cannabinoid has none.

For many minor cannabinoids, scientists do not yet have enough high-quality human data to answer that question confidently.

CBG, CBN, CBC, THCV and other minor cannabinoids are sometimes marketed as gentler alternatives because they do not produce the same intoxication as THC.

But long-term safety, medication interactions, reproductive effects and appropriate doses remain poorly characterized for many of them.

Product quality adds another variable.

A bottle labeled CBN or CBG may contain other cannabinoids, residual solvents, pesticides, heavy metals or concentrations that differ from the label if manufacturing and testing standards are poor.

Consumers should distinguish between:

Evidence that a cannabinoid appears well tolerated in a small trial

Evidence that it is safe after long-term use

Evidence that a commercial product containing it is accurately manufactured

Those are three different questions.

Yes. Products containing THC can produce a positive marijuana drug test, including some products marketed primarily for their CBD content.

Common urine tests screen for a THC metabolite, a substance the body produces as it breaks down THC. They do not simply test for every cannabinoid discussed in this guide.

Pure CBD is different from THC. In a small controlled study, Johns Hopkins researchers found that a single exposure to pure CBD did not produce a positive result under standard federal urine-testing criteria. However, a CBD-dominant cannabis product containing a small amount of THC produced positive results in some participants.

Full-spectrum products may contain THC, making their actual composition important for anyone subject to testing. Labels such as “broad-spectrum,” “CBD isolate” or “THC-free” should not be treated as guarantees. Johns Hopkins researchers have detected THC in some retail CBD products labeled “THC-free.”

The same practical question applies to products marketed for CBG, CBN or other minor cannabinoids: what else does the product contain?

A laboratory report matching the product’s batch can help readers evaluate its contents, but it cannot guarantee a negative drug test. Being marketed as non-intoxicating does not establish that a finished product is free of THC.

Cannabinoid science has progressed enormously, but large gaps remain.

Researchers understand THC much better than they did several decades ago.

CBD has become an FDA-approved medicine for specific seizure disorders.

Human trials are beginning to test minor cannabinoids that were previously studied almost entirely in animals.

But for most of the approximately 150-plus phytocannabinoids identified in marijuana, basic questions remain unanswered.

Researchers still need better information about:

Optimal dosing

Long-term safety

Drug interactions

Human metabolism

Differences between oral and inhaled formulations

Interactions between cannabinoids

Interactions with terpenes

Effects in older adults

Effects during pregnancy

Effects on developing brains

Medical applications

Whether laboratory findings translate into clinically meaningful effects

The cannabinoid alphabet is expanding much faster than the clinical evidence.

Cannabinoids are chemical compounds that can interact with the body’s cannabinoid signaling systems and other biological targets. Marijuana produces numerous phytocannabinoids, including THC, CBD, CBG, CBN and CBC.

THC and CBD are the two most studied and widely recognized cannabinoids.

THC is the primary intoxicating cannabinoid in marijuana. CBD is non-intoxicating and has a substantially different pharmacological profile.

Scientists have identified well over 100 phytocannabinoids. Recent reviews describe more than 150, with some estimating around 160 minor cannabinoids.

Delta-9 THC is the principal cannabinoid responsible for marijuana’s high.

Some related compounds may also be intoxicating, but claims that compounds such as THCP are a specific number of times stronger than THC have not been established in humans.

Yes. CBD, or cannabidiol, is one of the two most extensively studied phytocannabinoids.

“Stronger” is not a scientifically useful comparison.

CBG and CBD have different pharmacological profiles. Neither typically produces the THC high, and their effects cannot be reduced to one being stronger than the other.

The term is common but imprecise.

CBGA is the central acidic precursor that the marijuana plant uses to produce THCA, CBDA and CBCA. CBG forms primarily when CBGA decarboxylates.

CBN has shown some promising sleep-related results in controlled human research, but findings are mixed and the evidence remains limited.

It has not been established as a proven sleep medication.

THCV has been studied for metabolic effects, but there is not enough human evidence to establish it as an effective appetite suppressant or weight-loss treatment.

THCA itself does not produce the classic THC high.

However, heat converts THCA into intoxicating THC. Smoking, vaping or cooking a high-THCA product can therefore produce substantial intoxication.

That has not been demonstrated in humans.

A laboratory study found that THCP had approximately 33 times greater binding affinity for CB1 receptors than delta-9 THC. Binding affinity does not directly equal human potency.

Small amounts of delta-8 THC occur naturally in cannabis.

However, concentrated commercial delta-8 is commonly manufactured by chemically converting CBD because the natural plant contains too little delta-8 for efficient large-scale extraction.

No.

THC directly activates CB1 and CB2 receptors, but many other cannabinoids have weak activity at those receptors or work primarily through different molecular targets.

No.

Terpenes are a separate class of aromatic compounds that contribute heavily to marijuana’s smell and flavor.

Not reliably.

CBD and THC can interact, but their relationship depends on dose, ratio and route of administration. High oral doses of CBD have actually been shown to increase THC exposure and some THC effects under controlled conditions.

Some cannabinoid-based medications are FDA approved for specific medical conditions.

That does not mean every cannabinoid or every marijuana product has been proven to treat disease.

There is currently no scientific basis for saying that minor cannabinoids as a group are better.

They are simply less studied compounds with different pharmacological properties.

Some may eventually become useful medicines. Others may prove less important as clinical research develops.

Cannabinoids are not a single substance and should not be discussed as though they all produce the same effects.

THC is the primary intoxicating cannabinoid in marijuana and acts strongly through CB1 receptors.

CBD is non-intoxicating and has a much more complex pharmacological profile, with strong clinical evidence for certain seizure disorders but much less certain evidence for many of the conditions for which consumer CBD products are marketed.

CBG has entered early controlled human research, including a small trial that found reductions in anxiety and stress.

CBN has attracted intense interest for sleep, but human research remains limited and mixed.

CBC is scientifically promising but still lacks meaningful clinical evidence.

THCV has unusual dose-dependent pharmacology and some human metabolic research, but claims that it is an appetite-suppressing “diet cannabinoid” are premature.

CBDV has undergone clinical trials, including a seizure study that did not outperform placebo.

THCA, CBDA and CBGA are important acidic cannabinoids, particularly for understanding how the marijuana plant produces the compounds consumers ultimately encounter.

THCP illustrates one of the biggest problems in modern cannabinoid marketing: an interesting laboratory finding can quickly become a much stronger consumer claim than the evidence supports.

Cannabinoid science is advancing quickly. The most important distinction for consumers, patients and researchers is not whether a cannabinoid sounds promising.

It is whether the claim being made has been demonstrated in cells, animals or actual controlled human trials.

Those are very different levels of evidence.

This guide was prepared using peer-reviewed research and information from authoritative scientific and government sources, including:

Research into cannabinoids is developing rapidly. The Marijuana Herald will update this guide as meaningful new human evidence becomes available.